CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Olanzapine, risperidonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00034892
NCT00034892Phase 3Completed
CompareCT.gov

Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomized Double Blind 52-Week Comparison

AstraZeneca·interventional·Posted May 3, 2002·Updated Jan 4, 2013

In Brief

A Phase 3 clinical trial evaluating Olanzapine, risperidone for Schizophrenia and 3 related conditions. Completed, across 26 sites in 2 countries.

Detailed Summary

The purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day) and risperidone (0.5-4 mg/day) in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder who are experiencing their first psychotic episode.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Psychotic Disorders, Mental Health, Mental Disorders
CountriesCanada, United States
CollaboratorsUniversity of North Carolina

Timeline

Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 3, 2002
Enrollment StartMar 1, 2002
Primary CompletionMar 1, 2005
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 24.2 years ago

Interventions

Olanzapine, risperidonedrug